News|Articles|May 30, 2018
New EDoF IOL from ZEISS: optimal for elderly cataract patients with active lifestyle
Author(s)Pascal Rozot, MD
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5









































